ES2534588T3 - Terfenadine as an antiangiogenic agent - Google Patents

Abstract

Use of terfenadine in the preparation of a medicament for the inhibition of the growth or metastasis of an angiogenesis-dependent tumor selected from a human or human breast ovarian tumor in a patient in need thereof.

Description

fifteen

25

35

Four. Five

55

65 E11188941

04-08-2015

DESCRIPTION

Terfenadine as an antiangiogenic agent.

Technical field

The present disclosure relates generally to the treatment or prevention of diseases associated with angiogenesis by the administration in the patient of certain compounds that have been found to substantially inhibit or reduce angiogenesis. The compounds used according to the present disclosure have a good antiangiogenic activity, also demonstrating a prophylactic effect in the prevention and substantial reduction of angiogenesis. Examples of these compounds include ritanserin, amiodarone, terfenadine, perphenazine, bitionol and clomipramide.

Background

Angiogenesis is the formation of new blood vessels from preexisting capillaries and is a sequence of events that is of key importance in many physiological and pathological processes. Normal tissue growth, such as embryonic development, wound healing and the menstrual cycle, is characterized by the dependence of the formation of new vessels for the supply of oxygen and nutrients, as well as the elimination of waste products . A large number of different unrelated diseases are also associated with the formation of new vasculature. Among certain pathologies are conditions in which angiogenesis is reduced and must be increased in order to improve disease conditions. Pathologies that involve inadequate formation of blood vessels include peripheral and coronary ischemia and infarction, chronic failure of wound healing and ulcers. However, more frequently excessive angiogenesis is an important characteristic of various pathologies, including pathologies characterized or associated with abnormal or uncontrolled proliferation of cells. Pathologies that involve excessive angiogenesis include, for example, cancer (both solid and hematological tumors), cardiovascular diseases (such as atherosclerosis and restenosis), chronic inflammation (rheumatoid arthritis, Crohn's disease), diabetes (diabetic retinopathy), psoriasis, endometriosis, neovascular glaucoma and adiposity. See Griffioen and Molema, Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation, Pharmacol. Rev. 52: 237-268, 2000.

In general terms, the angiogenesis process involves the proliferation and migration of a normally inactive endothelium, the controlled proteolysis of the pericellular matrix and the synthesis of components of the new extracellular matrix by developing capillaries. The establishment of new intracellular and intercellular contacts and the morphological differentiation of endothelial cells in tubular capillary networks provide support for subsequent maturation, branching, remodeling and selective regression, forming a highly organized functional microvascular network. The autocrine, paracrine and amphoteric interactions of the vascular endothelium with its surrounding stromal components, as well as with proangiogenic and angiostatic cytokines and growth factors that control physiological angiogenesis, are usually closely regulated both spatially and temporally. See Gasparini, The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasia, Drugs 58 (1): 11-38, 1999.

The best known anti-angiogenesis agents with target in the proliferation of endothelial cells are the inhibitors of vascular endothelial growth factor ("FCEV"). FCEV, a potent angiogenic growth factor, is overexpressed in most solid human tumors and in ophthalmic disorders associated with the retina. FCEV receptors are enriched primarily in endothelial cells that transduce FCEV signaling in many pathological conditions of angiogenesis. Growth-stimulated endothelial cells are also sensitive to tyrosine kinase inhibitors with target in FCEV receptors, such as the recent FDA-approved anti-cancer drugs Sunitinib (SU11248) and Srafenib (BAY 43-9006). Anti-FCEV agents and FCEV receptors can stop the proliferation of endothelial cells and block the growth of new blood vessels. In addition to the FCEV, many other growth factors, such as fibroblast growth factors (FCF) and platelet-derived growth factors (FCDP) also play important roles in endothelial activation. Recently, resistance to antiangiogenic agents with a target only in FCEV signaling is emerging, presumably due to the existence of other alternative signaling pathways mediated by other growth factors.

Angiogenesis is crucial for the growth of neoplastic tissues. It has been observed for more than 100 years that tumors are more vascular than normal tissues. Some experimental studies have suggested that both primary tumor growth and metastasis require neovascularization. In contrast to the well-organized process described above for normal tissue growth, the pathological angiogenesis necessary for active tumor growth is generally sustained and persistent, with the initial acquisition of the angiogenic phenotype being a common mechanism in the development of a variety of types. of solid and hematopoietic tumor. See Folkman J., Cancer Medicine 132-152 (5th ed., B.C. Decker Inc., 2000).

fifteen

25

35

Four. Five

55

65 E11188941

04-08-2015

Tumors that cannot recruit and sustain a vascular network typically remain dormant in the form of asymptomatic lesions in situ. Metastasis is also dependent on angiogenesis: in order for a tumor cell to metastasize successfully, it must generally access the vasculature in the primary tumor, survive the circulation, stop at the microvasculature of the target organ, leave this vasculature, grow in the target organ and induce angiogenesis at the target site. In this way, angiogenesis is apparently necessary both at the beginning and at the end of the metastatic cascade.

The critical nature of angiogenesis for the growth and metastasis of neoplasms thus provides an optimal potential target for chemotherapeutic efforts. Suitable antiangiogenic agents can act directly or indirectly by influencing tumor-associated angiogenesis by delaying the appearance (ie, blocking an "angiogenic switch") or by blocking sustained and focal neovascularization that is characteristic of many types of tumor. Anti-angiogenesis therapies directed against the tumor-associated endothelium and the multiple processes and molecular and cellular targets involved in sustained pathological angiogenesis are being actively evaluated for safety and efficacy in multiple clinical trials. See Deplanque and Harris, Anti-angiogenic Agents: Clinical Trial Design and Therapies in Develoment, Eur. J. Cancer 36: 1713-1724, 2000. However, to date there has been little success in the discovery and / or identification of agents safe and / or effective antiangiogenic.

WO 96/26712 refers to the use of angiogenesis suppressants, including terfenadine, to inhibit hair growth.

WO 2006/017185 discloses drugs for the treatment of neoplastic disorders. The use of terfenadine is described in the treatment of cancer but not in the treatment of tumors. Two groups of compounds are identified. One group includes terfenadine and is reported as a treatment for cancer in general, not for tumors. A second group of compounds is reported as having a substantial antiproliferative activity against human tumor cells but does not include terfenadine.

Liu, J-D et al .; Molecular Mechanism of G0 / G1 Cell-Cycle Arrest and Apoptosis Induced by Terfenadine in Human Cancer Cells; MOLECULAR CARCINOGENESIS; 37: 39-50 (2003), describes the use of terfenadine for colon cancer and leukemia.

Jangi, S-M, et al .; H1 histamine receptor antagonist induces genotoxic and caspase-2-dependent apoptosis in human melanoma cells; Carcinogenesis; vol. 27; P. 1787-1796, March 28, 2006; describes the use of terfenadine for the treatment of skin tumors (malignant melanoma).

Summary

The present disclosure relates generally to the treatment or prevention of diseases associated with angiogenesis.

In one embodiment, the invention relates to terfenadine for use in methods of growth inhibition or metastasis of an ovarian or human breast tumor dependent on angiogenesis.

Brief description of the drawings

Figure 1 represents the dose-response curve drawn versus concentration for cell proliferation assays using ritanserin.

Figure 2 represents the results of an endothelial cell migration assay using ritanserin and the graph represents the percentage of cells that have migrated from a control.

Figure 3 represents the results of an endothelial tube formation assay using ritanserin and the graph represents the percentage of tubule formation relative to a control.

Figure 4 represents the results of an ex vivo MCA angiogenesis assay using ritanserin and the graph represents the vascular density index.

Figure 5 depicts the microvessel density results of an in vivo mouse assay of Matrigel three-dimensional matrix using ritanserin.

Figure 6 represents the results of a mouse xenograft model trial using ritanserin and the graph represents the change in tumor volume over time.

Figure 7 represents the dose-response curve drawn versus concentration for cell proliferation assays in which amiodarone hydrochloride is used.

E11188941

04-08-2015

Figure 8 represents the results of an endothelial cell migration assay using amiodarone hydrochloride and the graph represents the percentage of cells that have migrated from a control.

5 Figure 9 represents the results of an endothelial cell migration assay using amiodarone hydrochloride and the graph represents the percentage of tubule formation relative to a control.

Figure 10 represents the results of an ex vivo angiogenesis assay in MCA using amiodarone and the graph represents the vascular density index.

10 Figure 11 depicts the dose-response curve drawn versus concentration for cell proliferation assays using terfenadine.

Figure 12 represents the results of an endothelial cell migration assay using terfenadine and the graph represents the percentage of cells that have migrated from a control.

Figure 13 represents the results of an endothelial tube formation assay using terfenadine and the graph represents the percentage of tubule formation relative to a control.

20 Figure 14 represents the results of an ex vivo MCA angiogenesis test using terfenadine and the graph represents the vascular density index.

Figure 15 depicts the dose-response curve drawn versus concentration for cell proliferation assays using perfenazine.

Figure 16 represents the results of an endothelial cell migration assay using perfenazine and the graph represents the percentage of cells that have migrated from a control.

Figure 17 represents the results of an endothelial tube formation assay using perfenazine and the graph represents the percentage of tubule formation relative to a control.

Figure 18 depicts the dose-response curve drawn versus concentration for cell proliferation assay using bitionol.

35 Figure 19 represents the results of an endothelial cell migration assay using bitionol and the graph represents the percentage of cells that have migrated from a control.

Figure 20 represents the results of an endothelial tube formation assay using bitionol and the graph represents the percentage of tubule formation relative to a control.

40 Figure 21 represents the results of an ex vivo MCA angiogenesis assay using bitionol and the graph represents the vascular density index.

Figure 22 depicts the dose-response curve drawn versus concentration for cell proliferation assays using clomipramine.

Figure 23 represents the results of an endothelial cell migration assay using clomipramine and the graph represents the percentage of cells that have migrated from a control.

50 Figure 24 represents the results of an endothelial tube formation assay using clomipramine and the graph represents the percentage of tubule formation relative to a control.

Figure 25 represents the results of an ex vivo MCA angiogenesis assay using clomipramine and the graph represents the vascular density index. 55

Detailed description of the disclosure

The present disclosure refers in general to the treatment or prevention of diseases associated with angiogenesis in a patient who requires it, by administering in the patient certain

60 compounds that have been found to substantially inhibit or reduce angiogenesis. However, objects that are not within the scope according to the claims are not part of the present invention.

As previously used and throughout the disclosure, the following terms, unless otherwise indicated, should be appreciated that they have the following meanings.

10

fifteen

twenty

25

30

35

40

Four. Five

fifty

55

60

65 E11188941

04-08-2015

The term "alkyl" refers to an aliphatic hydrocarbon group that can be linear, branched or cyclic and has between 1 and about 10 carbon atoms in the chain, and all combinations and subcombinations of the intervals in said range. The term "branched" refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl or propyl, is attached to a linear alkyl chain. In certain embodiments, the alkyl group is a C1-C4 alkyl group, that is, a branched or linear alkyl group having between 1 and about 4 carbons. In other embodiments, the alkyl group is a C1-C3 alkyl group, that is, a branched or linear alkyl group having between 1 and about 3 carbons. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl.

The term "aryl" refers to an aromatic carbocyclic radical containing between about 6 and about 10 carbons, and all combinations and subcombinations of the ranges within said range. The aryl group may optionally be substituted with one or two or more substituents. Exemplary aryl groups include monocyclic groups, such as phenyl, and bicyclic groups, such as naphthyl.

The term "heteroaryl" refers to an aromatic carbocyclic radical containing between about 4 and about 10 elements, and all combinations and subcombinations of intervals within said range, in which one or more of the elements is a different element of carbon. , for example nitrogen, oxygen or sulfur. Exemplary heteroaryl groups include monocyclic groups, such as pyridyl, and bicyclic groups, such as indolyl.

The term "arylalkyl" refers to an alkyl substituted with an aryl group. A "C1-C4 arylalkyl group", for example, has a C1-C4 alkyl group substituted with an aryl group.

The term "heteroarylalkyl" refers to an alkyl substituted with a heteroaryl group. A "C1-C4 heteroarylalkyl group", for example, has a C1-C4 alkyl group substituted with a heteroaryl group.

The term "cycloalkyl" used alone or as part of a larger fraction will include cyclic C3-C10 hydrocarbons that are completely saturated or that contain one or more unsaturation units, but are not aromatic. Cycloaliphatic groups are typically C3-C10, more typically C3-C7.

The term "non-aromatic heterocycle", used alone or as part of a larger fraction, such as "heterocycloalkyl," refers to non-aromatic ring systems that typically have five to fourteen elements, preferably five to ten, in the that one or more annular carbons, preferably one to four, are each substituted by a heteroatom, such as N, O or S.

The term "effective amount" refers to an amount of a compound as indicated herein that may be therapeutically effective for treating a disease or disorder associated with angiogenesis. The exact amount of these compounds that is required will vary with the particular or used compounds, the age and condition of the subject to be treated, and the nature and severity of the condition. However, the effective amount can be determined by an ordinary person skilled in the art by only routine experimentation.

The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or forms of administration that are, within the scope of reasonable medical criteria, suitable for contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response or other problematic complications to the extent of a reasonable benefit / risk ratio.

The term "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds in which the parent compound is modified by the preparation of acid or base salts thereof. The compounds of the present disclosure form acid and base addition bases with a wide variety of organic and inorganic acids and bases and include the physiologically acceptable salts that are frequently used in pharmaceutical chemistry. Said salts are also part of the present exhibition. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, iohydric, nitric, sulfuric, phosphoric, hypophosphoric acids and the like. Salts derived from organic acids, such as aliphatic mono- and di-carboxylic acids, phenyl substituted alconic acids, hydroxyalkanoic and hydroxyalkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids can also be used. Thus, said pharmaceutically acceptable salts include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromobutyrate, bromide , butin-1,4-dioate, hexin-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, format, fumarate, glycolate, heptanoate, hippurate, lactate, malate, maleate, hydroxyleate, malonate, mandelate, mesylate , nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzene -sulfonate, pbromobenzenesulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p- toluenesulfonate, xylenesulfonate, tartrate and the like.

fifteen

25

35

Four. Five

55

65 E11188941

04-08-2015

Commonly used bases for salt formation include ammonium hydroxide and alkali and alkaline earth metal hydroxides, carbonates, as well as primary, secondary and tertiary aliphatic amines, and aliphatic diamines. Especially useful bases in the preparation of addition salts include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, methylamine, diethylamine and ethylenediamine.

The term "patient" refers to animals, including mammals, preferably humans.

The term "metabolite" refers to any substance resulting from chemical changes involved in the growth and repair processes in a living organism, including anabolic and catabolic processes.

A "prodrug" is a compound that is converted into the body in its active form, which has a medical effect. Prodrugs may be useful in the event that the active drug is excessively toxic for systemic administration, the drug is poorly absorbed in the digestive tract, or the body degrades the active drug before it reaches its target. Prodrug preparation methods are disclosed in Hans Bundgaard, Design of Prodrugs (Elsevier Science Publishers B.V., 1985).

The term "solvates" refers to the compound formed by the interaction of a solvent and a solute and includes hydrates. Solvents are usually crystalline solid adducts containing solvent molecules within the crystalline structure, in stoichiometric or non-stoichiometric proportions.

The term "comprising" (and its grammatical variations) as used herein is used in the inclusive sense of "presenting" or "including" and not in the exclusive sense of "consisting solely of". The term "consisting essentially of" as used herein is intended to mean that it includes what is explicitly indicated in conjunction with what does not materially affect the basic and new characteristics of the indicated or specified.

The terms "a", "one and" the or "the" as used herein are understood to comprise the plural as well as the singular, unless the context clearly indicates otherwise.

Certain acidic or basic compounds of the present exposure may be present in the form of zwitterions. All forms of the compound, including free acid, free base and zwitterions, are contemplated to be within the scope of the present disclosure.

Methods of synthesizing compounds, including terfenadine, are well known in the art and are disclosed in US Patent No. 3,878,217 to Carr et al. and in US Patent No. 4,254,129 to Carr et al.

In certain embodiments, the present disclosure relates to methods for inhibiting angiogenesis and / or for inhibiting the growth or metastasis of a tumor. As used herein, the term "inhibits" refers to the level of tumor growth or metastasis and / or the incidence of angiogenesis in patients who have received a compound, as described herein, it may be desirably reduced compared to patients who have not received said compound. Thus, in one way, the methods of inhibiting the present exposure comprise administering in an patient an effective amount of an antiangiogenic agent. The term "antiangiogenic agent", as used herein, refers to compounds that can inhibit angiogenesis.

In other embodiments, the exposure refers to methods for treating a disease or disorder associated with angiogenesis. These methods may include the step of identifying a patient presenting with said disease, including patients who would benefit from the treatment methods described herein. Diseases or disorders associated with angiogenesis include, for example, conditions in which angiogenesis plays a role in the pathology or progression of the condition, so that inhibition of angiogenesis in a patient presenting with such a condition could delay or block the further progression of the condition, or lead to remission or regression of the disease state. Such conditions are often characterized or associated with abnormal cell proliferation and include, for example, neoplastic diseases. As used herein, the term "treat a disease or disorder" refers to the administration of agents intended to limit the degree, progression and / or severity of a condition in a patient, as compared to patients who have not Been treated this way. As used herein, the term "neoplastic disease" refers to any condition characterized by the presence of aberrant growth of abnormal cells or tissues, including, but not limited to, all cancers and tumors, whether benign or malignant. . The term "treat a neoplastic disease" refers to the administration of a chemotherapeutic agent that will inhibit the further growth or metastasis of any neoplastic tissue that may exist in a patient and / or that will stimulate the regression of said neoplasms, including reducing the size. and / or number of said neoplasms and / or induction of the death of neoplastic cells.

Prodrug forms of compounds having various nitrogen functions (amino, hydroxyamino, amide, etc.) may include the following types of derivatives, in which each R group can individually be hydrogen, or a substituted or unsubstituted alkyl group , aryl, alkenyl, alkynyl, heterocycle, alkylaryl, aralkyl,

fifteen

25

35

Four. Five

55 E11188941

04-08-2015

aralkenyl, aralkynyl, cycloalkyl or cycloalkenyl, as defined above.

(to)

Carboxamides, -NHC (O) R,

(b)

carbamates, -NHC (O) OR,

(C)

(acyloxy) alkyl carbamates, NHC (O) OROC (O) R,

(d)

enamines, -NHCR (= CHCO2R) or -NHCR (= CHCONR2),

(and)

Schiff bases, -N = CR2,

(F)

Mannich bases (from carboximide compounds), RCONHCH2NR2.

The preparation of said prodrug derivatives is discussed in various literature sources (examples: Alexander et al., J. Med. Chem. 31: 318, 1988; Aligas-Martin et al., PCT document WO pp / 41531 , p 30). The nitrogen function converted during the preparation of said derivatives is one (or more) of the nitrogen atoms of a compound of the invention.

Prodrug forms of carboxyl-bearing compounds of the invention include esters (-CO2R) in which the R group corresponds to any alcohol whose release in the body by enzymatic or hydrolytic processes is at pharmaceutically acceptable levels. Another prodrug derived from a carboxylic acid form of the invention may be a quaternary salt type structure:

image 1

described by Bodor et al., J. Med. Chem. 23: 469, 1980.

It is obviously understood that the compounds of the present invention refer to all optical isomers and stereoisomers in the various possible atoms of the molecule.

Pharmaceutically acceptable salts of the compounds of the present invention include pharmaceutically acceptable inorganic or organic acid derivatives. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic acids, benzoic, malonic, naphthalene-2-sulfonic, trifluoroacetic and benzenesulfonic. Salts derived from appropriate bases include alkali metals such as sodium and ammonium.

The compounds of the present invention can be synthesized by one skilled in the art from the present disclosure without the need for undue experimentation. Appropriate procedures are available in the chemical literature to prepare the necessary sugars or nucleosides. In this line, see Choi Jong-Ryoo, Kim Jeong-Min, Roh Kee-Yoon, Cho Dong-Gyu, Kim Jae-Hong, Hwang Jae-Taeg, Cho Woo-Young, Jan Hyun-Sook, Lee Chang-Ho, Choi Tae-Saeng, Kim Chung-Mi, Kim Yong-Zu, Kim Tae-Kyun, Cho Seung-Joo, Kim Gyoung-Won, patent application int. PCT, 100 pages, 2002, No. WO 0257288 A1 20020725. Holy Antonin, Votruba Ivan, Tloustova Eva, Masojidkova Milena. Collection of Czechoslovak Chemical Communications 66 (10): 1545-1592, 2001. Rejman Dominik, Masojidkova Milena, De Clercq Eric, Ivan Rosenberg, Nucleosides, Nucleotides & Nucleic Acids 20 (8): 1497-1522, 2001; Ubasawa Masaru, Skiya Kouichi, patent application int. PCT, 39 pages, 2001, No. WO 0164693 A1 20020907. Otmar Miroslav, Masojfdkova Milena, Ivan Votruba, Holy Antonin. Collection of Czechoslovak Chemical Communications 66 (3): 500-506, 2001. Michal, Hocek Michal, Holy Antonin. Collection of Czechoslovak Chemical Communications 65 (8): 1357-1373, 2000. Jeffery AL, Kim J.-H., Wiemer DF, Tetrahedron 56 (29): 50775083, 2000. Holy Antonin, Guenter Jaroslav, Dvorakova Hana, Masojidkova Milena Andrei Graciela, Snoeck Robert, Balzarini Jan, De Clercq Erik, Journal of Medicinal Chemistry 42 (12): 2064-2086, 1999. Janeba Zlatko, Holy Antonin, Masojidkova Milena. Collection of Czechoslovak Chemical Communications 66 (9): 1393-1406, 2001. Holy Antonin, Guenter Jaroslav, Dvorakova Hana, Masojidkova Milena, Andrei Graciela, Snoeck Robert, Balzarini Jan, De Clercq Erik. Journal of Medicinal Chemistry 42 (12): 2064-2086, 1999. Dan Qun, Erion Mark D., Reddy M. Rami, Robinsion Edward D., Kasibhatla Srinivas Rao, Reddy K. Raja. Int. patent application PCT, 126 pages, 1998, No. WO 9839344 A1 19980911. Arimilli Murty N., Cundy Kenneth C., Dougherty Joseph P., Kim Choung U., Oliyai Reza, Stella Valentino J., patent application int. PCT, 74 pages, 1998, No. WO 9804569. Sekiya Kouichi, Takashima Hideaki, Ueda Naoko, Kamiya Naohiro, Yuasa Satoshi, Fujimura Yoshiyuki, Ubasawa Masaru, Journal of Medicinal Chemistry 45 (14): 3138-3142, 2002. Ubasawa Masaru, Sekiya Kouichi, Takashima Hideaki, Ueda Naoko, Yuasa Satoshi, Kamiya Naohiro, Eur. Pat. Appl., 56 pages, 1997, No. EP 785208 A1 19970723. Hocek Michal, Masojidkova Milena, Holy Antonin, Collection of Czechoslovak Chemical Communications 62 (1): 136-146, 1997. Holy Antonin, Votruba Ivan, Tloustova Eva, Masojidkova Milena . Collection of Czechoslovak Chemical Communications 66 (10): 1545-1592, 2001. Holy Antonin, De Clercq, Erik Desire Alice, patent application int. PCT, 57 pages, 1996, No. WO 9633200 A1 19961024. Rejman Dominik, Rosenberg Ivan. Collection of Czechoslovak Chemical Communications 61 (special issue): S122-S123, 1996. Holy Antonin, Dvorakova Hana, Jindrich Jindrich, Masojidkova Milena, Budesinsky Milos, Balzarini Jan, Andrei Graciella, De Clercq Erik, Journal of Medicinal

fifteen

25

35

Four. Five

55

65 E11188941

04-08-2015

Chemistry 39 (20): 4073-4088, 1996. Guanti Giuseppe, Merlo Valeria, Narisano Enrica, Tetrahedron 51 (35): 9737-46, 1995. Takashima Hideaki, Inoue Naoko, Ubasawa Masaru, Sekiya Kouichi, Yabuuchi Shingo, request for EU Patent, 88 pages, 1995, No. EP 632048 A1 19950104. Alexander Petr, Holy Antonin, Masojidkova Milena, Collection of Czechoslovak Chemical Communications 59 (8): 1853-69, 1994. Alexander Petr, Holy Antonin, Masojidkova Milena, Collection of Czechoslovak Chemical Communications 59 (8): 1853-69, 1994. Jindrich Jindrich, Holy Antonin, Dvorakova Hana. Collection of Czechoslovak Chemical Communications 58 (7): 1645-67, 1993. Holy Antonin, Collection of Czechoslovak Chemical Communications 58 (3): 649-74, 1993. Guanti Giuseppe, Merlo Valeria, Narisano Enrica, Tetrahedron 51 (35): 9737-46, 1995. Emishetti Purushotham, Brodfuehrer Paul R., Howell Henry G., Sapino Chester Jr., patent application int. PCT, 43 pages, 1992, No. WO 9202511 A1 19920220. Glazier Arnold. Int. Patent application PCT, 131 pages, 1991, No. WO 9119721. Kim Choung Un, Lu Bing Yu, Misco Peter F., Bronson Joanne J., Hitchcock Michael JM, Ghazzouli Ismail, Martin John C., Journal of Medicinal Chemistry 33 (4): 1207-13, 1990. Rosenberg Ivan, Holy Antonin, Masojidkova Milena. Collection of Czechoslovak Chemical Communications 53 (11B): 2753-77, 1988. Rosenberg Ivan, Holy Antonin, Masojidkova Milena. Collection of Czechoslovak Chemical Communications 53 (11B): 2753-77, 1988.

The following examples illustrate and describe aspects of this presentation.

Example 1

Cell Proliferation Assay

Primary human arterial endothelial cell lines, such as CEAH, CEAPH, CEVCU venous endothelium (from Cambrex BioScience Rockland Inc.) and LL47 pulmonary fibroblasts (from the American Type Culture Collection) were cultured following the instructions and used to evaluate target compounds for differential activity against human endothelial versus fibroblasts by the CellTiter-Glo luminescent cell viability assay. This assay, which generates luminescent signals, is based on the quantification of ATP levels in cell cultures. The amount of ATP produced in the cell culture reflects the number of viable cells. Therefore, this assay is frequently used to estimate cell proliferation and cytotoxic effects of test compounds. Cells were seeded in 96-well plates with their growth medium, approximately 5x103 cells per well. After 24 hours, various doses of the test compounds were added to the cultures, preparing four replicates for each dose. After 72 hours of treatment, the CellTiter-Glo reagent was added to the cultures following the manufacturer's instructions and the luminescence was measured. Control groups received only DMSO vehicle. The IC50 of the target compounds for endothelial and fibroblast proliferation in their growth medium were determined based on the dose-response curve and plotted against the concentration range.

Example 2

Endothelial Cell Migration Assay

Endothelial cell migration is a key stage in the angiogenesis process, which is crucial for the in situ recruitment of blood vessel formation. The Trans-well filter / insert chamber of the Biocoat Endothelial Cell Migration Angiogenesis System (BD Biosciences) was used for the endothelial cell migration assay, which is a plate with 24 Trans-well chamber containing inserts 3 µm in size. pore coated with human fibronectin. The inserts were incubated at 37 ° C with 0.1% bovine serum albumin containing basal endothelial cell medium for 1 hour. Endothelial cells (CEVCU) were fasted with 0.1% bovine serum albumin in basal endothelial cell medium for 4 to 5 hours before cell collection and then seeded (1x105 per well) in upper chambers of the Trans-well plate with various treatments in 100 µl of 0.1% bovine serum albumin in basal endothelial cell medium. Complete growth medium containing various chemoattractants was added in the lower chambers. The cells were allowed to migrate for 22 ± 1 hours at 37 ° C. Cells that had not migrated inside the inserts were carefully removed with a Q-tip swab. Cells that had migrated to the bottom of the Trans-well inserts were then fixed with 4% paraformaldehyde, stained with Hoechst 33342 and photographed under a fluorescence microscope. Three microscopy fields of view of each filter / insert were analyzed for the number of migrated cells. Triplicate filter / chamber insert cultures were carried out for each test concentration and control. The data is expressed as the average number of cells that have migrated through each microscopy field of view at 10x magnification and the IC50 was calculated based on the dose curve.

Example 3

Endothelial tube formation test

Human endothelial cells were cultured in vitro on extracellular matrix, which stimulates the adhesion and differentiation of endothelial cells in tubules. The endothelial tube formation test is based on this phenomenon. Endothelial cells (CEVCU) (1.5x104 in each well) were seeded in a 96-well plate coated with extracellular matrix and treated with the target compounds at different concentrations with the medium.

10

fifteen

twenty

25

30

35

40

Four. Five

fifty

55

60

65 E11188941

04-08-2015

of full growth in triplicate. The cells were allowed to form endothelial tubes at 37 ° C for approximately 18 hours and photographed under an inverted light microscope. The lengths of the tubules were quantified using image analysis software, Image-Pro Plus (Media Cybernetics, Inc., Siler Spring, MD). Data were expressed as mean tube lengths of three fields of vision for each well and triplicate wells for each treatment condition. IC50 values were calculated based on the dose curve.

Example 4

Chicken Chorioallantoic Membrane (MCA) Assay

The chorioallantoic membrane of the chicken embryo provides an ideal in vivo model for the physiological process of angiogenesis. Angiogenic modulators applied to methylcellulose discs located on the chorioallantoic chicken embryo membrane are capable of altering the development of the new blood vasculature. See Staton et al., Current Methods for Assaying Angiogenesis in vitro and in vivo, Int. J. Exp. Pathol. 85: 233-48, 2004. The angiogenesis chorioallantoic membrane assay was used for ex vivo evaluation of the angiogenic potential of synthetic compounds. Fertilized chicken eggs were incubated at 37.5 ° C in a humidified egg incubator with forced air circulation. On embryonic day 3, the eggs were opened and the embryos were transferred to 100 mm 3 Petri dishes to continue their development in a cell culture incubator at 37.5 ° C. Pre-prepared methylcellulose discs approximately 2 mm in diameter were carefully implanted on top of the embryonic chorioallantoic membrane on embryonic day 5 and then applied on the test compound methylcellulose disk in solution or control vehicle. Embryos were incubated for two more days in the cell culture incubator. Chorioallantoic membranes were examined and the formation of new blood vessels was analyzed quantitatively on embryonic day 7. The effects of treatment were evaluated by determining the vascular density index (IDV) of each MCA with viable chicken embryos. The IDV represents the number of intersections made by blood vessels with three concentric equidistant circles in the area covered by methylcellulose discs using Image Pro Plus software. Data are expressed as mean IDV based on quantitative analysis for each treatment group (N≥5) with standard deviation.

Example 5

Matrigel three-dimensional matrix mouse assay

The Matrigel three-dimensional matrix assay is an in vivo assay of new blood vessel formation widely used for the evaluation of the antiangiogenic activities of synthetic compounds and recombinant proteins. C57BL / 6 female mice of approximately 8 to 10 weeks and high concentration Matrigel matrix were used for the three-dimensional Matrigel matrix experiments. Four or five mice were used for each treatment group and two three-dimensional matrices of Matrigel in each mouse. The Matrigel was mixed with 50 ng / ml of FCEV, 50 ng / ml of FCDP b and 3 ng / ml of heparin as angiogenic stimuli. The target compounds at different doses were mixed with Matrigel or i.p. or i.v. or orally. Matrigel was injected subcutaneously at 4 ° C, 500 µl of Matrigel for each matrix, on each mouse flank, where the coat had been shaved. The injected Matrigel quickly forms a single solid gel matrix. Matrices of each group were collected approximately two weeks after Matrigel inoculation. The mice were euthanized by inhalation of CO2 and the mouse skin was removed to expose the matrix. The intact matrices were removed and fixed in 10% formalin for histological analysis. Sections (5 µm thick) of matrices included in paraffin were immunostained, with specific antibody against CD31 and stained with H&E. A count of the positive microvessels for CD31 was performed in a complete cross-sectional area of each three-dimensional Matrigel matrix. For each group of mice, approximately six Matrigel matrices were analyzed quantitatively in order to evaluate any statistically significant difference in microvessel density between the control and compound treated groups.

Example 6

Antitumor efficacy of compounds evaluated by the xenograft model in nude mouse

Tumor growth depends on angiogenesis. Inhibition of tumor angiogenesis has become an effective treatment for cancer. Standard nude mouse xenograft models were used to evaluate potential antiangiogenic agents for their antitumor activity. Human tumor cells or fragments were implanted in nude mice 5 to 7 weeks old. Target compounds were administered in each group of mice via i.p., i.v. or oral Tumor size and body weight of mice were monitored twice a week. The mean tumor volumes at each time point are expressed with standard deviation versus the time of tumor growth, which is in days after xenograft inoculation.

Procedures such as those described in the previous examples were used to obtain the data presented in the figures and in Table I, below.

5

10

fifteen

twenty

25

30

35

40

Four. Five

50 E11188941

04-08-2015

Table 1

Compound

IC50 (µM) arterial endothelial proliferation IC50 (µM) venous endothelial proliferation IC50 (µM) fibroblast proliferation Inhibition of endothelial migration Inhibition of endothelial tube formation Inhibition in MCA assay (10 µg)

2 µM

8 µM  2 µM 8 µM

Ritanserin *

11.0 10.5 > 50 55% 65% eleven% 33% twenty-one%

Amiodarone Hydrochloride *

7.5 8.8 20.0 36% 38% 33% 33% 27%

Terfenadine

3.0 5.5 7.0 3. 4% 100% twenty% 43% 28%

Clomipramine Hydrochloride *

10.8 4,5 28.0 58% 63% 12% 26% 19%

Perphenazine *

4.2 11.1 10.8 43% 46% 7% 22% -

Bitionol *

2.0 6.0 10.5 5% 100% 19% 38% 30%

* Reference examples

Formulations

The compounds of the present disclosure can be administered by any conventional means available for use in conjunction with pharmaceuticals, as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, although they are generally administered with a selected pharmaceutical carrier based on the selected route of administration and standard pharmaceutical practice. The compounds can also be co-administered with other therapeutic agents, such as interferon (IFN), interferon-α-2a, interferon-α-2b, consensus interferon (IFNC), ribavirin, amantadine, remantadine, interleukin-12, ursodeoxycholic acid ( ACUC) and glycyrrhizin.

The pharmaceutically acceptable carriers indicated herein, for example vehicles, adjuvants, excipients or diluents, are well known to those skilled in the art. Typically the pharmaceutically acceptable carrier is chemically inert for the active compounds and has no harmful side effects or toxicity under the conditions of use. Pharmaceutically acceptable carriers may include polymers and polymer matrices.

The compounds of the present disclosure can be administered by any conventional method available for use in conjunction with pharmaceuticals, as individual therapeutic agents or in a combination of therapeutic agents.

The dose administered will obviously vary according to known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the type of concurrent treatment, the frequency of treatment and the desired effect. A daily dose of active ingredient can be expected to be between about 0.001 and 1000 milligrams (mg) per kilogram (kg) of body weight, with a preferred dose being between 0.1 and about 60 mg / kg.

Administration forms (compositions suitable for administration) contain between about 1 mg and about 500 mg of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will usually be present in an amount of between about 0.5 and 95% by weight based on the total weight of the composition.

The active substance can be administered orally in solid administration forms, such as capsules, tablets and powders, or in liquid administration forms, such as elixirs, syrups and suspensions. It can also be administered parenterally, in sterile liquid administration forms. The active substance can also be administered intranasally (nasal drops) or by inhalation of aerosolized drug powders. Other forms of administration are potentially possible, such as transdermal administration, by means of a patch or ointment mechanism.

Formulations suitable for oral administration may consist of: (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline or orange juice, (b) capsules, sachets, tablets, pills and troches, each containing a predetermined amount of the active substance, in the form of solids or granules, (c) powders, (d) suspensions in an appropriate liquid, and (e) suitable emulsions. Liquid formulations may include diluents, such as water and alcohols, for example ethanol, benzyl alcohol, propylene glycol, glycerin and polyethylene alcohols, with or without the addition of a pharmaceutically acceptable surfactant, suspending agent or emulsifying agent. The capsule forms may be of the ordinary hard or soft type containing, for example, surfactants, lubricants and inert fillers, such as lactose, sucrose, calcium phosphate and corn starch. Tablet forms may include

fifteen

25

35

Four. Five

55

65 E11188941

04-08-2015

one or more of the following: lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talcum, magnesium stearate, stearate calcium, zinc stearate, stearic acid and other excipients, colorants, diluents, buffering agents, disintegrating agents, wetting agents, preservatives, flavoring agents and pharmacologically compatible carriers. The tablet forms may comprise the active ingredient in a flavoring, usually sucrose and acacia or tragacanth, as well as tablets comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions and gels they contain, in addition to the active ingredient, carriers such as those known in the art.

The compounds of the present exposure, alone or in combination with other suitable components, can be prepared in aerosol formulations for administration by inhalation. These aerosol formulations can be introduced into pressurized acceptable propellants, such as dichlorodifluoromethane, propane and nitrogen. They can also be formulated as pharmaceuticals for non-pressurized preparations, such as in a nebulizer

or in an atomizer.

Suitable formulations for parenteral administration include sterile isotonic, aqueous and non-aqueous injection solutions, which may contain antioxidants, buffers, bacteriostats and solutes that convert the formulation into isotonic with the desired recipient's blood, and non-aqueous and sterile suspensions. aqueous which may include suspending agents, solubilizers, thickening agents, stabilizers and preservatives. The compound can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose solutions and related sugars, an alcohol, such as ethanol, isopropanol or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, such as poly (ethylene glycol) 400, glycerol ketals, such as 2,2, -dimethyl-1,3-dioxollan-4-methanol, ethers, an oil, a fatty acid, an ester or glyceride of fatty acid, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methyl cellulose, hydroxypropyl methylcellulose or carboxymethyl cellulose,

or emulsifying agents and other pharmaceutical adjuvants.

The oils, which can be used in parenteral formulations, include crude oil and animal, vegetable and synthetic oils. Concrete examples of oils include peanut, soy, sesame, cottonseed, corn, olive, petroleum jelly and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters. Suitable soaps for use in parenteral formulations include the alkali metal, ammonium and triethanolamine fatty salts, and suitable detergents include: (a) cationic detergents such as, for example, dimethyldialkyl ammonium halides and alkylpyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl and olefin sulfonates, and alkyl, olefin, ether and monoglyceride sulfates, and sulphosuccinates, (c) non-ionic detergents such as, for example, oxides fatty amine, fatty acid alkanolamides and polyoxyethylene-polypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl β-aminopropionates and quaternary ammonium 2-alkylimidazoline salts, and (e) mixtures thereof.

Parenteral formulations typically contain between about 0.5% and about 25% by weight of the active ingredient in solution. Suitable preservatives and buffers can be used in these formulations. In order to minimize or eliminate irritation at the injection site, such compositions may contain one or more non-ionic surfactants that have a hydrophilic-lipophilic balance (EHL) of between about 12 and about 17. The amount of surfactant in said Formulations are between about 5% and about 15% by weight. Suitable surfactants include sorbitan-polyethylene fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.

Pharmaceutically acceptable excipients are also well known to those skilled in the art. The choice of excipient will be determined in part by the particular compound, as well as by the particular method used to administer the composition. In accordance with the foregoing, there is a wide variety of suitable formulations of the pharmaceutical composition of the present disclosure. Pharmaceutically acceptable excipients preferably do not interfere with the action of the active ingredients and do not cause adverse side effects. Suitable carriers and excipients include solvents such as water, alcohol and propylene glycol, solid adsorbents and diluents, surface active agents, suspending agents, tableting binders, lubricants, flavorings and coloring agents.

The formulations can be presented in single-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) state that requires only the addition of sterile liquid excipient, for example water, for injections immediately before use. . Solutions and suspensions for extemporaneous injection can be prepared from sterile powders, granules and tablets. The requirements for effective pharmaceutical carriers for injectable compositions are well known to those of ordinary skill in the art (5, 6). See Banker and Chalmers, Pharmaceutics and Pharmacy

E11188941

04-08-2015

Practice, 238-250 (J.B. Lippincott Co., Philadelphia, PA, editors, 1982) and Toissel, ASHP Handbook on Injectable Drugs, 622-630 (4th ed., 1986).

Suitable formulations for topical administration include pills that comprise the principle

5 active in a flavoring, usually sucrose and acacia or tragacanth, tablets comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, and mouthwashes comprising the active ingredient in a suitable liquid carrier, thus as creams, emulsions and gels containing, in addition to the active ingredient, carriers such as those known in the art.

In addition, formulations suitable for rectal administration may be presented in the form of suppositories by mixing with a variety of bases such as emulsifying bases or water soluble bases. Formulations suitable for vaginal administration may be presented in the form of pessaries, buffers, creams, gels, pastes, foams or aerosol formulas containing, in addition to the active ingredient, carriers known in the art that are appropriate.

15 Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.

The dose administered in an animal, particularly a human being, in the context of the present exposure

20 should be sufficient to affect the therapeutic response in an animal in a reasonable time frame. The person skilled in the art will appreciate that the dose will depend on a variety of factors, including the condition of the animal, the body weight of the animal, as well as the severity and stage of the condition under treatment.

An appropriate dose is one that will result in a concentration of the active agent in a patient that is known

25 that affects the desired response. The preferred dose is the amount that results in the maximum inhibition of the condition under treatment, without uncontrollable side effects.

The dose size will also be determined from the route, timing and frequency of administration, as well as the existence, nature and extent of any adverse side effects that may accompany

30 upon administration of the compound, and the desired physiological effect.

The pharmaceutical administration forms useful for the administration of the compounds according to the present exposure can be illustrated as follows:

35 Hardcover Capsules

A large number of unit capsules are prepared by filling two standard pieces of hard gelatin capsules, each with 100 mg of active ingredient powder, 150 mg of lactose, 50 mg of cellulose and 6 mg of magnesium stearate.

40 Soft gelatin capsules

A mixture of active ingredient is prepared in a digestible oil, such as soybean oil, cottonseed oil or olive oil, and injected by a positive displacement pump in molten gelatin to

45 form soft gelatin capsules containing 100 mg of the active substance. The capsules are washed and dried. The active substance can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a mixture of water-miscible medicines.

Tablets

A large number of tablets are prepared by conventional procedures so that the administration unit has 100 mg of active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of lactose. Appropriate aqueous and non-aqueous coatings may be applied to increase palatability, increase elegance and

55 stability or delay absorption.

Capsules / immediate-release tablets

They are solid oral administration forms prepared by conventional and new procedures. These

60 units are taken orally without water for immediate dissolution and administration of the medication. The active substance is mixed in a liquid that contains ingredients such as sugar, gelatin, pectin and sweeteners. These liquids solidify into solid tablets or capsules by lyophilization and solid phase extraction techniques. The drug compounds can be compressed with viscoelastic and thermoelastic sugars and effervescent polymers or components to produce porous matrices intended for immediate release, without the need for

65 water

E11188941

04-08-2015

In addition, the compounds of the present exposure can be administered in the form of nasal drops, or measured doses and a nasal or oral inhaler. The drug is administered from a nasal solution in the form of a fine mist or from powders in the form of an aerosol.

Claims (5)

1. Use of terfenadine in the preparation of a medicinal product intended for growth inhibition or metastasis of an angiogenesis-dependent tumor selected from a human ovarian tumor or human breast in a patient in need thereof. 2. Use according to claim 1, wherein the tumor is a breast tumor.

3.

Use according to claim 1, wherein the tumor is an ovarian tumor. 10

4. Use according to claim 1, wherein the medicament is intended for the inhibition of tumor growth.

5.

Use according to claim 1, wherein the medicament is intended for the inhibition of metastasis of a tumor.

14